| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Bone Oncology Group, Divisions of Clinical Sciences and Genomic Medicine, Medical School, University of Sheffield, Sheffield S10 2RX [I. H., F. C. H., C. L. E.]; Academic Urology Unit, Division of Clinical Sciences, Medical School, University of Sheffield S10 2RX [F. C. H., C. L. E.]; and Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD [P. I. C.] United Kingdom
Factors that aid survival of prostate cancer cells in the presence of the variouscategories of cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that inhibits TRAIL-induced apoptosis. In relation to this activity, we hypothesized that the ability to produce OPG by prostate cancer cells would confer a survival advantage on these cells. In this study we have demonstrated that high levels of OPG are produced by the hormone-insensitive prostate cancer cell lines PC3 and Du145, whereas the hormone-sensitive cell line LNCaP produced 10–20-fold less OPG under the same conditions. A strong negative correlation was observed between levels of endogenously produced OPG in the medium and the capacity of TRAIL to induce apoptosis in cells that produced high levels of OPG. The antiapoptotic effect of OPG was reversed by coadministration of 100-fold molar excess of receptor-activator of nuclear factor-
B ligand, another protein that selectively binds OPG. These observations suggest that prostate cancer-derived OPG may be an important survival factor in hormone-resistant prostate cancer cells.
This article has been cited by other articles:
|
|
 |
|
  P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells Blood, February 1, 2008; 111(3): 1287 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lawrie, E. Waterman, M. Southwood, D. Evans, J. Suntharalingam, S. Francis, D. Crossman, P. Croucher, N. Morrell, and C. Newman Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary Arterial Hypertension Am. J. Pathol., January 1, 2008; 172(1): 256 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vega, N. M. Maalouf, and K. Sakhaee The Role of Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/Osteoprotegerin: Clinical Implications J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4514 - 4521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Locklin, E. Federici, B. Espina, P. A. Hulley, R. G. G. Russell, and C. M. Edwards Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis Mol. Cancer Ther., December 1, 2007; 6(12): 3219 - 3228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vitovski, J. S. Phillips, J. Sayers, and P. I. Croucher Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-{kappa}B or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS J. Biol. Chem., October 26, 2007; 282(43): 31601 - 31609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zauli, F. Corallini, F. Bossi, F. Fischetti, P. Durigutto, C. Celeghini, F. Tedesco, and P. Secchiero Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo Blood, July 15, 2007; 110(2): 536 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carlo-Stella, C. Lavazza, A. Locatelli, L. Vigano, A. M. Gianni, and L. Gianni Targeting TRAIL Agonistic Receptors for Cancer Therapy Clin. Cancer Res., April 15, 2007; 13(8): 2313 - 2317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C Perez-Martinez, V. Alonso, J. L Sarasa, S.-G. Nam-Cha, R. Vela-Navarrete, F. Manzarbeitia, F. J Calahorra, and P. Esbrit Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand J. Clin. Pathol., March 1, 2007; 60(3): 290 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Heath, K. Vanderkerken, X. Cheng, O. Gallagher, M. Prideaux, R. Murali, and P. I. Croucher An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma Cancer Res., January 1, 2007; 67(1): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S S Cross, R F Harrison, S P Balasubramanian, J M Lippitt, C A Evans, M W R Reed, and I Holen Expression of receptor activator of nuclear factor {kappa}{beta} ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables J. Clin. Pathol., July 1, 2006; 59(7): 716 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Fisher, R. J. Thomas-Mudge, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, T. J. Martin, and M. T. Gillespie Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res., April 1, 2006; 66(7): 3620 - 3628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Van Poznak, S S Cross, M Saggese, C Hudis, K S Panageas, L Norton, R E Coleman, and I Holen Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor {kappa}B ligand (RANKL) in human breast tumours J. Clin. Pathol., January 1, 2006; 59(1): 56 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Asirvatham, M. Schmidt, B. Gao, and J. Chaudhary Androgens Regulate the Immune/Inflammatory Response and Cell Survival Pathways in Rat Ventral Prostate Epithelial Cells Endocrinology, January 1, 2006; 147(1): 257 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Corey, L. G. Brown, J. A. Kiefer, J. E. Quinn, T. E.M. Pitts, J. M. Blair, and R. L. Vessella Osteoprotegerin in Prostate Cancer Bone Metastasis Cancer Res., March 1, 2005; 65(5): 1710 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Colucci, G. Brunetti, R. Rizzi, A. Zonno, G. Mori, G. Colaianni, D. Del Prete, R. Faccio, A. Liso, S. Capalbo, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction Blood, December 1, 2004; 104(12): 3722 - 3730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Harada, Y. Osuga, T. Hirata, Y. Hirota, K. Koga, O. Yoshino, C. Morimoto, T. Fujiwara, M. Momoeda, T. Yano, et al. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis Hum. Reprod., October 1, 2004; 19(10): 2188 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Hofbauer and M. Schoppet Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases JAMA, July 28, 2004; 292(4): 490 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Cheng, M. Kinosaki, M. Takami, Y. Choi, H. Zhang, and R. Murali Disabling of Receptor Activator of Nuclear Factor-{kappa}B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo J. Biol. Chem., February 27, 2004; 279(9): 8269 - 8277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller Soluble Receptor Activator of Nuclear Factor {kappa}B Fc Diminishes Prostate Cancer Progression in Bone Cancer Res., November 15, 2003; 63(22): 7883 - 7890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yonou, N. Kanomata, M. Goya, T. Kamijo, T. Yokose, T. Hasebe, K. Nagai, T. Hatano, Y. Ogawa, and A. Ochiai Osteoprotegerin/Osteoclastogenesis Inhibitory Factor Decreases Human Prostate Cancer Burden in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice Cancer Res., May 1, 2003; 63(9): 2096 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Shipman and P. I. Croucher Osteoprotegerin Is a Soluble Decoy Receptor for Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo2 Ligand and Can Function as a Paracrine Survival Factor for Human Myeloma Cells Cancer Res., March 1, 2003; 63(5): 912 - 916. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
